PALISADE BIO, INC. Research and Development Expense
PALISADE BIO, INC. (PALI) reported Research and Development Expense of $6.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- PALISADE BIO, INC. research and development expense for the quarter ending 2026-06-30 was $6.00M.
- PALISADE BIO, INC. research and development expense for the quarter ending 2026-03-31 was $6.00M.
- PALISADE BIO, INC. research and development expense for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. research and development expense for the quarter ending 2024-09-30 was $16.00M.
- PALISADE BIO, INC. research and development expense for fiscal 2024 was $16.00M.
- PALISADE BIO, INC. research and development expense for fiscal 2020 was $2.02M, a 50.30% decline from fiscal 2019.
- PALISADE BIO, INC. research and development expense for fiscal 2019 was $4.06M, a 2.56% increase from fiscal 2018.
- PALISADE BIO, INC. research and development expense for fiscal 2018 was $3.96M, a 51.09% decline from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.00M 10-Q · filed 2026-08-10 | $12.00M 10-Q · filed 2026-08-10 | ||||||
| 2026-03-31 | $6.00M 10-Q · filed 2026-05-12 | |||||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-20 | $16.00M derived: sum of 2 quarters · filed 2026-03-20 | $16.00M 10-K · filed 2026-03-20 | |||||
| 2024-09-30 | $16.00M 10-Q · filed 2025-11-10 | $16.00M 10-Q · filed 2025-11-10 | ||||||
| 2023-12-31 | $362.00K 10-Q · filed 2024-11-12 | |||||||
| 2021-03-31 | $471.11K 10-Q · filed 2021-05-14 | $880.63K derived: sum of 2 quarters · filed 2021-05-14 | $1.35M derived: sum of 3 quarters · filed 2021-05-14 | $1.79M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2020-12-31 | $409.52K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $875.53K derived: sum of 2 quarters · filed 2021-03-22 | $1.32M derived: sum of 3 quarters · filed 2021-03-22 | $2.02M 10-K · filed 2021-03-22 | ||||
| 2020-09-30 | $466.01K 10-Q · filed 2020-11-10 | $912.05K derived: sum of 2 quarters · filed 2020-11-10 | $1.61M 10-Q · filed 2020-11-10 | $2.38M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2020-06-30 | $446.03K 10-Q · filed 2020-08-13 | $1.14M 10-Q · filed 2020-08-13 | $1.91M derived: sum of 3 quarters · filed 2021-05-14 | $2.74M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2020-03-31 | $696.89K 10-Q · filed 2021-05-14 | $1.46M derived: sum of 2 quarters · filed 2021-05-14 | $2.29M derived: sum of 3 quarters · filed 2021-05-14 | $3.24M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | $767.05K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $1.59M derived: sum of 2 quarters · filed 2021-03-22 | $2.55M derived: sum of 3 quarters · filed 2021-03-22 | $4.06M 10-K · filed 2021-03-22 | ||||
| 2019-09-30 | $825.49K 10-Q · filed 2020-11-10 | $1.78M derived: sum of 2 quarters · filed 2020-11-10 | $3.29M 10-Q · filed 2020-11-10 | $4.17M derived: sum of 4 quarters · filed 2020-11-10 | ||||
| 2019-06-30 | $954.45K 10-Q · filed 2020-08-13 | $2.47M 10-Q · filed 2020-08-13 | $3.35M derived: sum of 3 quarters · filed 2020-08-13 | $4.24M derived: sum of 4 quarters · filed 2020-08-13 | ||||
| 2019-03-31 | $1.51M 10-Q · filed 2020-05-15 | $2.39M derived: sum of 2 quarters · filed 2020-05-15 | $3.29M derived: sum of 3 quarters · filed 2020-05-15 | $4.31M derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | $878.87K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $1.78M derived: sum of 2 quarters · filed 2020-03-27 | $2.79M derived: sum of 3 quarters · filed 2020-03-27 | $3.96M 10-K · filed 2020-03-27 | ||||
| 2018-09-30 | $897.10K 10-Q · filed 2019-11-14 | $1.91M derived: sum of 2 quarters · filed 2019-11-14 | $3.08M 10-Q · filed 2019-11-14 | $4.31M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $1.01M 10-Q · filed 2019-08-14 | $2.18M 10-Q · filed 2019-08-14 | $3.41M derived: sum of 3 quarters · filed 2019-08-14 | $4.79M derived: sum of 4 quarters · filed 2019-08-14 | ||||
| 2018-03-31 | $1.17M 10-Q · filed 2019-05-14 | $2.39M derived: sum of 2 quarters · filed 2019-05-14 | $3.78M derived: sum of 3 quarters · filed 2019-05-14 | $6.36M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $2.61M derived: sum of 2 quarters · filed 2019-03-22 | $5.19M derived: sum of 3 quarters · filed 2019-03-22 | $8.10M 10-K · filed 2019-03-22 | ||||
| 2017-09-30 | $1.38M 10-Q · filed 2018-11-14 | $3.97M derived: sum of 2 quarters · filed 2018-11-14 | $6.87M 10-Q · filed 2018-11-14 | $10.90M derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2017-06-30 | $2.59M 10-Q · filed 2018-08-13 | $5.49M 10-Q · filed 2018-08-13 | $9.51M derived: sum of 3 quarters · filed 2018-08-13 | $13.10M derived: sum of 4 quarters · filed 2018-08-13 | ||||
| 2017-03-31 | $2.90M 10-Q · filed 2018-05-15 | $6.93M derived: sum of 2 quarters · filed 2018-05-15 | $10.52M derived: sum of 3 quarters · filed 2018-05-15 | $12.99M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | $4.03M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $7.62M derived: sum of 2 quarters · filed 2018-04-02 | $10.09M derived: sum of 3 quarters · filed 2018-04-02 | $13.16M 10-K · filed 2018-04-02 | ||||
| 2016-09-30 | $3.59M 10-Q · filed 2017-11-08 | $6.06M derived: sum of 2 quarters · filed 2017-11-08 | $9.13M 10-Q · filed 2017-11-08 | $11.88M derived: sum of 4 quarters · filed 2017-11-08 | ||||
| 2016-06-30 | $2.47M 10-Q · filed 2017-08-08 | $5.54M 10-Q · filed 2017-08-08 | $8.29M derived: sum of 3 quarters · filed 2017-08-08 | $11.68M derived: sum of 4 quarters · filed 2017-08-08 | ||||
| 2016-03-31 | $3.07M 10-Q · filed 2017-05-10 | $5.82M derived: sum of 2 quarters · filed 2017-05-10 | $9.21M derived: sum of 3 quarters · filed 2017-05-10 | $12.52M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2015-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-23 | $6.14M derived: sum of 2 quarters · filed 2017-03-23 | $9.45M derived: sum of 3 quarters · filed 2017-03-23 | $12.64M 10-K · filed 2017-03-23 | ||||
| 2015-09-30 | $3.39M 10-Q · filed 2016-11-08 | $6.70M derived: sum of 2 quarters · filed 2016-08-11 | $9.89M 10-Q · filed 2016-11-08 | $12.50M derived: sum of 4 quarters · filed 2016-08-11 | ||||
| 2015-06-30 | $3.31M 10-Q · filed 2016-08-11 | $6.50M 10-Q · filed 2016-08-11 | $9.11M derived: sum of 3 quarters · filed 2016-08-11 | $11.22M derived: sum of 4 quarters · filed 2016-08-11 | ||||
| 2015-03-31 | $3.18M 10-Q · filed 2016-05-09 | $5.80M derived: sum of 2 quarters · filed 2016-05-09 | $7.91M derived: sum of 3 quarters · filed 2016-05-09 | $9.91M derived: sum of 4 quarters · filed 2016-05-09 | ||||
| 2014-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $4.72M derived: sum of 2 quarters · filed 2016-03-14 | $6.72M derived: sum of 3 quarters · filed 2016-03-14 | $8.36M 10-K · filed 2016-03-14 | $8.13M 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $2.11M 10-Q · filed 2015-11-09 | $2.06M 10-Q · filed 2014-11-07 | $4.11M derived: sum of 2 quarters · filed 2015-11-09 | $5.75M 10-Q · filed 2015-11-09 | $5.58M 10-Q · filed 2014-11-07 | $7.52M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-06-30 | $2.00M 10-Q · filed 2015-08-10 | $1.95M 10-Q · filed 2014-08-08 | $3.63M 10-Q · filed 2015-08-10 | $3.52M 10-Q · filed 2014-08-08 | $5.41M derived: sum of 3 quarters · filed 2016-03-14 | $7.26M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-03-31 | $1.63M 10-Q · filed 2015-05-08 | $1.57M 10-Q · filed 2014-05-12 | $3.41M derived: sum of 2 quarters · filed 2016-03-14 | $5.26M derived: sum of 3 quarters · filed 2016-03-14 | $7.17M derived: sum of 4 quarters · filed 2016-03-14 | |||
| 2013-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $3.63M derived: sum of 2 quarters · filed 2016-03-14 | $5.54M derived: sum of 3 quarters · filed 2016-03-14 | $7.29M 10-K · filed 2016-03-14 | $7.13M 10-K · filed 2014-03-10 | |||
| 2013-09-30 | $1.85M 10-Q · filed 2014-11-07 | $3.75M derived: sum of 2 quarters · filed 2014-11-07 | $5.50M 10-Q · filed 2014-11-07 | $7.20M derived: sum of 4 quarters · filed 2015-03-16 | ||||
| 2013-06-30 | $1.91M 10-Q · filed 2014-08-08 | $3.65M 10-Q · filed 2014-08-08 | $5.35M derived: sum of 3 quarters · filed 2015-03-16 | $6.74M derived: sum of 4 quarters · filed 2015-03-16 | ||||
| 2013-03-31 | $1.75M 10-Q · filed 2014-05-12 | $3.45M derived: sum of 2 quarters · filed 2015-03-16 | $4.83M derived: sum of 3 quarters · filed 2015-03-16 | $6.43M derived: sum of 4 quarters · filed 2015-03-16 | ||||
| 2012-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $3.08M derived: sum of 2 quarters · filed 2015-03-16 | $4.68M derived: sum of 3 quarters · filed 2015-03-16 | $6.11M 10-K · filed 2015-03-16 | ||||
| 2012-09-30 | $1.39M 10-Q · filed 2013-11-12 | $2.98M derived: sum of 2 quarters · filed 2013-11-12 | $4.41M 10-Q · filed 2013-11-12 | $5.81M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-06-30 | $1.60M 10-Q · filed 2013-08-08 | $3.02M 10-Q · filed 2013-08-08 | $4.43M derived: sum of 3 quarters · filed 2014-03-10 | $6.55M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-03-31 | $1.42M 10-Q · filed 2013-05-10 | $2.83M derived: sum of 2 quarters · filed 2014-03-10 | $4.95M derived: sum of 3 quarters · filed 2014-03-10 | $7.04M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2011-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $3.53M derived: sum of 2 quarters · filed 2014-03-10 | $5.62M derived: sum of 3 quarters · filed 2014-03-10 | $7.35M 10-K · filed 2014-03-10 | ||||
| 2011-09-30 | $2.12M 10-Q · filed 2012-11-09 | $4.21M derived: sum of 2 quarters · filed 2012-11-09 | $5.95M 10-Q · filed 2012-11-09 | $8.49M derived: sum of 4 quarters · filed 2012-11-09 | ||||
| 2011-06-30 | $2.09M 10-Q · filed 2012-08-09 | $3.82M 10-Q · filed 2012-08-09 | $6.36M derived: sum of 3 quarters · filed 2012-08-09 | $8.47M derived: sum of 4 quarters · filed 2012-08-09 | ||||
| 2011-03-31 | $1.74M 10-Q · filed 2012-05-09 | $4.28M derived: sum of 2 quarters · filed 2012-05-09 | $6.39M derived: sum of 3 quarters · filed 2012-05-09 | $9.00M derived: sum of 4 quarters · filed 2012-05-09 | ||||
| 2010-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-30 | $4.65M derived: sum of 2 quarters · filed 2012-03-30 | $7.26M derived: sum of 3 quarters · filed 2012-03-30 | $9.16M 10-K · filed 2012-03-30 | ||||
| 2010-09-30 | $2.11M 10-Q · filed 2011-11-09 | $4.73M derived: sum of 2 quarters · filed 2011-11-09 | $6.63M 10-Q · filed 2011-11-09 | |||||
| 2010-06-30 | $2.61M 10-Q/A · filed 2011-09-23 | $4.51M 10-Q/A · filed 2011-09-23 | ||||||
| 2009-12-31 | $5.35M 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |